Skip to navigation Skip to main content
Oncology Nurse Advisor
  • Cancer Types
    • Cancer Types
      • Brain Cancer
      • Breast Cancer
      • Cervical Cancer
      • Chronic Myeloid Leukemia‎
      • Colorectal Cancer
      • Gastrointestinal Cancer
      • General Oncology
      • Genitourinary Cancer
      • Gynecologic Cancer
      • Head and Neck Cancer
      • Hematologic Cancers
      • Kidney Cancer
      • Leukemia
      • Liver Cancer
      • Lung Cancer
      • Lymphoma
      • Melanoma
      • Multiple Myeloma
      • Myeloproliferative Neoplasms
      • Ovarian Cancer
      • Pancreatic Cancer
      • Prostate Cancer
      • Sarcoma
      • Skin Cancer
  • Hot Topics
    • Hot Topics
      • Advisor Forum
      • Ask a Pharmacist
      • Ask the Experts
      • Communication Challenges
      • Complementary and Alternative Medicine
      • From CancerCare
      • General Medicine
      • Issues in Cancer Survivorship
      • Journal Review
      • Navigation
      • Oncology Nursing
      • Radiation and Your Patient
      • Reflections
      • Side-Effect Management
      • Stat Consult
      • The Patient’s Voice
      • The Total Patient
  • Regimens
  • Resources
    • Resources

      Clinical Tools

      • Clinical Charts
      • Drug Information Database
      • Medical Calculators

      Professional Resources

      • Expert Perspective
      • Decision Support in Medicine
      • Digital Issues
      • Job Board
      • Product Directory
      • Useful Links
  • For Patients
    • For Patients
      • Advocacy
      • Cancer Support Groups
      • Fact Sheets
      • Finding Clinical Trials
  • Conferences
    • Conferences

      Oncology Conferences

      • Conference Coverage

      News Resources

      • Daily Oncology News
      • Web Exclusives
  • ONA Summit
  • News
  • CE
  • Fact Sheets
  • Publishers Alliance
  • Navigation
  • Expert Perspective
  • Slideshows
  • Jobs

Home » Headlines

Publish Date October 7, 2015

Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Reddit
  • Print
  • Share by Email

the Oncology Nurse Advisor take:

An analysis of data from the Surveillance, Epidemiology, and End Results–Medicare database has found that sunitinib and sorafenib may be associated with an increased risk of cardiovascular events, particularly stroke, in older patients with renal cell carcinoma (RCC).

Sorafenib and sunitinib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for the treatment of RCC.

The population-based, observational cohort study analyzed patients ages 66 years or older with RCC diagnosed between 2000 and 2009. The researchers examined incidence of cardiovascular events, including congestive heart failure and cardiomyopathy (CHF/CM), acute myocardial infarction (AMI), stroke, and cardiovascular deaths through December 2010.

Of the 670 patients who received sorafenib or sunitinib, 171 had experienced a cardiovascular event. Use of either of the drugs was associated with an increased risk of cardiovascular events and especially stroke compared with 788 patients with advanced RCC diagnosed from 2007 to 2009 who did not receive either agent.

Subgroup analyses revealed that patients ages 66 to 74 years at diagnosis had the highest increased risk of stroke associated with use of sorafenib or sunitinib, or both.

Joint statement offers new recommendations for treating patients with cardiovascular conditions
Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma.

How to Cite Jang, S., Zheng, C., Tsai, H.-T., Fu, A. Z., Barac, A., Atkins, M. B., Freedman, A. N., Minasian, L. and Potosky, A. L. (2015), Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer.

READ FULL ARTICLE Curated publisher From Wiley Online Library

Topics:

Kidney Cancer Renal Cell Carcinoma
  • Loading...

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Next post in Headlines

Chemotherapy Use Associated with Survival Benefit Among Medicare Patients with SCLC

Back to Top
  • Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community online and in print. Daily online exclusives cover late breaking oncology news, safe handling and administration of chemotherapy drugs, side effect management, and new developments in specific cancers.

  • Resources
    • Editorial Board
    • Subscribe
    • Author Guidelines
    • Permissions
    • Reprints
  • User Center
    • About Us
    • Contact Us
    • Advertise
  • Other Haymarket Medical Websites
    • Cancer Therapy Advisor
    • Clinical Advisor
    • Clinical Pain Advisor
    • Dermatology Advisor
    • Endocrinology Advisor
    • Gastroenterology Advisor
    • Hematology Advisor
    • Infectious Disease Advisor
    • McKnight’s Long Term Care News
    • McKnight’s Senior Living
    • Medical Bag
    • MPR
    • myCME
    • Neurology Advisor
    • Ophthalmology Advisor
    • Optometry Advisor
    • Psychiatry Advisor
    • Pulmonology Advisor
    • Rare Disease Advisor
    • Renal and Urology News
    • Rheumatology Advisor
    • The Cardiology Advisor
  • Copyright © 2022 Haymarket Media, Inc. All Rights Reserved
    This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
    Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.

Loading...
Loading...
Loading...
Loading...